gabapentin NDC 50228-524

NDC codes

FDA NDC Directory

Product NDC (as listed)50228-524Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50228-0524Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
50228-524-05	50228052405	500 TABLET in 1 BOTTLE (50228-524-05)Marketed from Sep 20, 2025
50228-524-30	50228052430	30 TABLET in 1 BOTTLE (50228-524-30)Marketed from Sep 20, 2025
50228-524-90	50228052490	90 TABLET in 1 BOTTLE (50228-524-90)Marketed from Sep 20, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): gabapentin
Generic name (nonproprietary): gabapentin
Active ingredients: Gabapentin — 600 mg/1
Dosage form: Tablet
Route: Oral
Labeler: ScieGen Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 218491
Marketing start: Sep 20, 2025
Listing expires: Dec 31, 2026
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 50228-524_3f2e32c6-5993-0189-e063-6294a90a0ff6SPL ID 3f2e32c6-5993-0189-e063-6294a90a0ff6SPL set ID 3f2e3ac5-5233-fd57-e063-6294a90a849eRxCUI 1806380, 1806382UNII 6CW7F3G59XUPC 0350228523905

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450228052405 followed by a unit qualifier and the quantity

Package 50228-0524-05. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 1, 2025.

Indications (excerpt from the label)

Gabapentin tablets (Once-Daily) are indicated for the management of postherpetic neuralgia. Gabapentin tablets (Once-Daily) are not substitutable with other gabapentin products because of differing pharmacokinetic profiles that affect the frequency of administration. Gabapentin tablets are indicated for the management of Postherpetic Neuralgia (PHN). Important Limitation: Gabapentin tablets (Once-Daily) is not substitutable with other gabapentin products because of differing pharmacokinetic profiles that affect the frequency of administration ( See Warnings and Precautions )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 218491

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 218491
Product	Strength	Form · route	Labeler	Product NDC
gabapentin	Gabapentin 300 mg/1	TabletOral	ScieGen Pharmaceuticals, Inc.	50228-523